Biventricular mechanical replacement.
The role of biventricular mechanical support (assist or replacement) is important for the management of severe biventricular cardiac failure. One only has to look at the role of cardiac transplantation to realize the benefit of a natural therapy to end-stage heart disease. Although the technology today is not that different from the technology that existed a decade ago (ie, BioMedicus, BVS 5000, Thoratec, CardioWest), the application of it and the experience gained by it have allowed surgeons to improve the chances of a positive outcome. In terms of new technologies for biventricular mechanical support, the totally implantable versions of a VAD (eg, Thoratec IVAD) or the totally implantable TAH (eg, AbioCor) are promising technologies that add to the spectrum of devices as destination therapy or alternatives to transplantation. And lastly, the role of the Berlin Heart as a tool for the management of biventricular failure in pediatric patients may be realized in the United States in the near future. In conclusion, the treatment of biventricular failure (acute or chronic) with assist or replacement technologies has gained widespread acceptance in the medical and surgical communities. It is now time to use these technologies wisely in an effort to treat the worldwide epidemic of congestive heart failure.
Samuels
Louis
L
Heart Failure and Transplant Program, Lankenau Hospital Cardiothoracic Surgery, 100 Lancaster Avenue, Wynnewood, PA 19096, USA. samuelsle@aol.com
D000208:Acute Disease; D002908:Chronic Disease; D004867:Equipment Design; D004869:Equipment Safety; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*